The Pharma Letter ... Phase II, open-label study in patients with previously-treated multiple myeloma that evaluated two doses of the investigational monoclonal antibody elotuzumab (10mg/kg and 20mg/kg) in combination with lenalidomide and low-dose dexamethasone . and more »
DailyFinance Studies of elotuzumab in combination with lenalidomide and low-dose dexamethasone at a dose of 10 mg/kg are ongoing. ELOQUENT-1, a Phase 3 trial in first-...
Stockhouse Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previously-Treated Multiple Myeloma ... and more »
The Myeloma Beacon Ixazomib is an orally-administered proteasome inhibitor , the same class of drugs to which Velcade (bortezomib) and Kyprolis (carfilzomib) belong; it is being developed by Millennium Pharmaceuticals, the same company that developed and markets Velcade ...
